China's major vaccine maker Changchun Changsheng Life Sciences said its shares will resume trading during Monday's afternoon session, after receiving an investigation notice from the China Securities Regulatory Commission.
"If the outcome of the investigation by the regulator is that there has been a major violation of the law or if the case is sent to the police, the company's stock is likely to be suspended or terminated from the market," according to Changsheng's statement on the website of the Shenzhen Stock Exchange.
The company had suspended its shares from trading early on Monday, after it was suspected to be violating standards in making rabies vaccines for humans, sparking nationwide outrage online.
In a statement to the Shenzhen Stock Exchange on Sunday, the company said that its suspension of rabies vaccine production would have a significant impact on its finances and that some regional disease control agencies have already suspended the production of some of its other vaccines for humans.
The China Food and Drug Administration, China's drug regulator, said on Sunday that it had ordered Changsheng to stop production immediately and will launch an investigation into the company over its production of rabies vaccines for human use.
Chinese Premier Li Keqiang said in a statement that the Changsheng vaccine case has crossed a moral line and that the people deserve a clear explanation, according to a note on the website of the State Council, China's cabinet, on Sunday.
During morning trading on Monday, the domestic vaccine sector hit a collective limit down, which included Shenzhen Kangtai Biological Products Co and Changchun High & New Technology Industries Inc.
